Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
Aim<br> To identify people in English primary care with equivalent cardiovascular risk to participants in the sodium–glucose co‐transporter‐2 inhibitor (SGLT‐2i) cardiovascular outcome trials (CVOTs). A secondary objective was to report the usage of SGLT‐2is. <br><br> Methods<br...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2020
|
| _version_ | 1826260049925767168 |
|---|---|
| author | Hinton, W Feher, M Munro, N Joy, M de Lusignan, S |
| author_facet | Hinton, W Feher, M Munro, N Joy, M de Lusignan, S |
| author_sort | Hinton, W |
| collection | OXFORD |
| description | Aim<br>
To identify people in English primary care with equivalent cardiovascular risk to participants in the sodium–glucose co‐transporter‐2 inhibitor (SGLT‐2i) cardiovascular outcome trials (CVOTs). A secondary objective was to report the usage of SGLT‐2is.
<br><br>
Methods<br>
Cross‐sectional analysis of people registered with participating practices in the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network on the 31 December 2016. We derived: (1) proportions of the primary care population eligible for inclusion in each SGLT‐2i CVOT (CANVAS, DECLARE, EMPA‐REG and VERTIS); (2) characteristics of the eligible population compared with trial participants (demographics, disease duration and vascular risk); and (3) differences within the eligible population prescribed SGLT‐2is.<br><br>
Results<br>
The proportions of people with type 2 diabetes (N = 84 394) meeting the inclusion criteria for each CVOT were: DECLARE 27% [95% confidence interval (CI) 26.5–27.1]; CANVAS 17% (16.6–17.1); VERTIS 7% (7.1–7.4); and EMPA‐REG 7% (6.5–6.8). Primary care populations fulfilling inclusion criteria were 5–8 years older than trial cohorts, and <10% with inclusion criteria of each trial were prescribed an SGLT‐2i; a greater proportion were men, and of white ethnicity.
<br><br>
Conclusions<br>
There was variation in proportions of the primary care type 2 diabetes population fulfilling inclusion criteria of SGLT‐2i CVOTs. The more stringent the inclusion criteria, the lower the proportion identified in a primary care setting. Prescription rates for SGLT‐2is were low in this national database, and there were demographic disparities in prescribing. |
| first_indexed | 2024-03-06T18:59:27Z |
| format | Journal article |
| id | oxford-uuid:1303626a-abf9-4f14-8a87-b5ba18ba4b6b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:59:27Z |
| publishDate | 2020 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:1303626a-abf9-4f14-8a87-b5ba18ba4b6b2022-03-26T10:11:24ZSodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary careJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1303626a-abf9-4f14-8a87-b5ba18ba4b6bEnglishSymplectic ElementsWiley2020Hinton, WFeher, MMunro, NJoy, Mde Lusignan, SAim<br> To identify people in English primary care with equivalent cardiovascular risk to participants in the sodium–glucose co‐transporter‐2 inhibitor (SGLT‐2i) cardiovascular outcome trials (CVOTs). A secondary objective was to report the usage of SGLT‐2is. <br><br> Methods<br> Cross‐sectional analysis of people registered with participating practices in the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network on the 31 December 2016. We derived: (1) proportions of the primary care population eligible for inclusion in each SGLT‐2i CVOT (CANVAS, DECLARE, EMPA‐REG and VERTIS); (2) characteristics of the eligible population compared with trial participants (demographics, disease duration and vascular risk); and (3) differences within the eligible population prescribed SGLT‐2is.<br><br> Results<br> The proportions of people with type 2 diabetes (N = 84 394) meeting the inclusion criteria for each CVOT were: DECLARE 27% [95% confidence interval (CI) 26.5–27.1]; CANVAS 17% (16.6–17.1); VERTIS 7% (7.1–7.4); and EMPA‐REG 7% (6.5–6.8). Primary care populations fulfilling inclusion criteria were 5–8 years older than trial cohorts, and <10% with inclusion criteria of each trial were prescribed an SGLT‐2i; a greater proportion were men, and of white ethnicity. <br><br> Conclusions<br> There was variation in proportions of the primary care type 2 diabetes population fulfilling inclusion criteria of SGLT‐2i CVOTs. The more stringent the inclusion criteria, the lower the proportion identified in a primary care setting. Prescription rates for SGLT‐2is were low in this national database, and there were demographic disparities in prescribing. |
| spellingShingle | Hinton, W Feher, M Munro, N Joy, M de Lusignan, S Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care |
| title | Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care |
| title_full | Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care |
| title_fullStr | Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care |
| title_full_unstemmed | Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care |
| title_short | Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care |
| title_sort | sodium glucose co transporter 2 inhibitor cardiovascular outcome trials and generalizability to english primary care |
| work_keys_str_mv | AT hintonw sodiumglucosecotransporter2inhibitorcardiovascularoutcometrialsandgeneralizabilitytoenglishprimarycare AT feherm sodiumglucosecotransporter2inhibitorcardiovascularoutcometrialsandgeneralizabilitytoenglishprimarycare AT munron sodiumglucosecotransporter2inhibitorcardiovascularoutcometrialsandgeneralizabilitytoenglishprimarycare AT joym sodiumglucosecotransporter2inhibitorcardiovascularoutcometrialsandgeneralizabilitytoenglishprimarycare AT delusignans sodiumglucosecotransporter2inhibitorcardiovascularoutcometrialsandgeneralizabilitytoenglishprimarycare |